WO2001043725A1 - Controlled release kci tablet formulations - Google Patents
Controlled release kci tablet formulations Download PDFInfo
- Publication number
- WO2001043725A1 WO2001043725A1 PCT/US2000/033924 US0033924W WO0143725A1 WO 2001043725 A1 WO2001043725 A1 WO 2001043725A1 US 0033924 W US0033924 W US 0033924W WO 0143725 A1 WO0143725 A1 WO 0143725A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- ethylcellulose
- potassium chloride
- tablet
- parts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
Definitions
- K-DUR 20 there is a 20 mEq KCI tablet that is commercially available under the tradename, K-DUR 20, based on KCI granules coated with a coating composition comprising of ethyl cellulose (Ethocel Standard Premium 100 or Ethocel Medium 100 from Dow Chemical) and hydroxypropyl cellulose (Klucel from Hercules) using a fluid bed granulator which is made under U.S. Patent 4,863,743 issued to C. Hsiao and T. Chou of Key Pharmaceuticals, Inc.
- An object of the present invention is to provide a method for manufacturing pharmaceutically elegant KCI tablets having sustained release properties (e.g., releasing not more than 40% in one hr and not less than 80% over 8 hrs when tested in USP Apparatus 2 (Paddles @ 50 rpm) in purified water.
- Another object is to provide tablets with controlled release characteristics, thereby providing treatments for potassium deficiency in humans while minimizing adverse side effects if possible. Since 20 mEq active is equivalent to almost 1500 mg Kcl, it is difficult to provide this dosage in a single tablet, which can deliver an effective daily dose of potassium without being unduly large for swallowing.
- a more particular but non-limiting further objective of the invention is to provide tablets of total tablet weight of about 2 g (preferably under 2 g) with acceptable hardness (not less than 10 kP) and friability (not more than 1.5%).
- US Patent 5,422,122 teaches the art of making a pharmaceutical dosage form by first forming KCI microcapsules by coacervation in a cyclohexane solution of ethylcellulose, overcoating the microcapsules with hydroxypropylcellulose and compressing the resulting microcapsules into 20 mEq KCI tablets This patent is incorporated here in its entirety Microencapsulated KCI granules produced by solvent coacervation of ethylcellulose aie often glassy haid granules with poor compactibihty characteristics.
- polymeric materials found suitable for improving ethylcellulose coated KCI microcapsules include acacia, alginic acid or its salt, com starch, gelatin, xanthan gum, polyvinylpyrrohdone (PVP), sodium carboxymethylcellulose. methylcellulose, low molecular weight ethylcellulose (EC) and hydroxypropylmethyl cellulose (HPMC) alone or in combination.
- PVP polyvinylpyrrohdone
- HPMC hydroxypropylmethyl cellulose
- one manifestation of the present invention is an improved 20 mEq KCI controlled release dosage form prepared from a multiplicity of ethylcellulose microencapsulated potassium chloride crystals, which are further coated with a plasticized water swellable/soluble polymer or a blend. These membrane coated granules are capable of being compressed into pharmaceutically elegant, easily swallowable 20 mEq KCI tablets of acceptable hardness and friability Of course other KCI dosages are also within the scope of the invention.
- Another manifestation of the present invention is a method for preparing microencapsulated KCI crystals and a method for preparing a KCL tablet
- a plurality of potassium chloride crystals preferably from about 20 mesh to about 70 mesh, more preferably from about 30 mesh to about 50 mesh, are coated with two distinct layers.
- the first layer applied to the crystals is composed of ethylcellulose. Utilization of a high viscosity ethylcellulose such as one with a viscosity of from about 90 to about 1 10 cp, e.g., Ethocel 100 (Dow Chemical Corp.) allows the crystals to retain their diffusion controlling characteristics even after compression into a tablet form.
- the ethylcellulose may be applied by any suitable technique known in the art, but is preferably applied by coacervation using polyethylene as a phase separator as described in U. S. Patent 5,422,122. If coacervation is used, trace amounts of the phase separator may be present in the first layer, preferably in an amount less than about one percent by weight of the ethylcellulose coated crystals.
- the ethylcellulose layer is preferably applied to the KCI crystals in an amount of about 8 to about 20 percent, more preferably from about 1 1 to about 15 percent, of the total weight of the uncoated potassium chloride crystals.
- This first layer controls the release of the potassium chloride over time, total release time being proportionally dependent upon the thickness of ethylcellulose.
- a drying step should preferably be carried out for such a time period and at such temperatures so that the microencapsulated crystals do not adhere to one another.
- the resultant ethylcellulose encapsulated potassium chloride microcapsules are preferably of such a size that less than 5% are greater than 20 mesh.
- a second, discrete layer of at least one hydrophilic (water swellable/soluble) polymer coating is applied over the first layer of ethylcellulose.
- Hydrophilic polymer coatings include, but are not necessarily limited to acacia, alginic acid or its salt, corn starch, gelatin, xanthan gum, polyvinylpyrrolidone (PVP), sodium carboxymethylcellulose, methylcellulose, low molecular weight ethylcellulose (Ethocel with a viscosity from about 4 to 20 cps) and hydroxypropylmethyl cellulose (HPMC) such as Methocel E5 or 15.
- PVP polyvinylpyrrolidone
- HPMC hydroxypropylmethyl cellulose
- the hydrophilic polymer layer is plasticized.
- suitable plasticizers include triacetin, triethyl citrate, dibutyl sebacate (DBS), polyethylene glycol (PEG) of molecular weight ranging from 200 to 8,000 (e.g., a blend of PEG 400 and PEG 4000).
- the plasticizers can be used alone or in combination.
- the plasticizer is typically used in an amount of about 2 to 30% based on the combined weight of the hydrophillic polymer and plasticizer. The amount will vary with the type of plasticizer and the nature of the hydrophillic polymer. For example for HPMC and PEG400 the ratio can vary trom about 70/30 to 90/10 With PVP, DBS or triethyl citrate can be used as the plasticizer in a ratio of 94/6 to 97/3.
- the plasticized hydrophilic layer is applied by conventional techniques, such as from an aqueous solution using a fluidized bed coater, to the preformed layer of ethylcellulose.
- the hydrophilic polymer coating layer inclusive of the plasticizer is applied m an amount of about 0.5 to 5% w/w (preferably about 1 to 3% w/w and still more typically 2% w/w) of the weight of the ethylcellulose coated crystals.
- the hydrophilic polymer does not significantly diffuse into the ethylcellulose, but rather forms a distinct second layer.
- the first membrane of ethylcellulose coacervated in the absence of any plasticizer can be easily distinguishable from the plasticized polymeric membrane by microscopic/spectroscopic techniques.
- the hydrophilic polymer coating dissolves following ingestion of the resultant tablet
- the hydrophilic polymer coating is present primarily as a binder material so that a high dosage rate tablet can be formed with a minimal amount of conventional excipients and low compaction pressures to allow minimal disruption of the rate controlling ethylcellulose membrane
- this formulation allows the microencapsulated potassium chloride to be dispersed essentially mtact over a wide area, reducing the risk of gastric irritation.
- the now twice coated crystals are subjected to a final drying step.
- the resultant coated potassium chloride microcapsules are preferably of such a size that less than 15%, are greater than 20 mesh.
- the coated crystals may then be formed into tablets by compression using conventional techniques.
- a minimal amount of excipients no more than about 15% more preferably no more than 12%, and most preferably no more than 7% by weight based on the weight of the final dosage tablet, is added to the coated crystals prior to compression.
- excipients refers to any additional pharmaceutically acceptable ingredients which may be used in a tablet.
- excipients include, but are not limited to, ingredients such as diluents or binders, dismtegrants, wetting agents, and lubricating agents.
- Representative binders include, but are not limited to, Klucel Registered LF (hydroxypropylcellulose) and Avicel Registered (microcrystallme cellulose).
- Dismtegrants include, but are not limited to, cornstarch, lactose, mannitol, sucrose, Avicel Registered (microcrystallme cellulose), P ⁇ mogel Registered (sodium carboxymethyl starch, Emcompress Registered (dibasic calcium phosphate dihydrate), Crospovidone Registered (cross linked polyvinyl pyrrolidone), and tricalcium phosphate.
- Wetting agents include, but are not limited to sodium lauryl sulfate.
- Lubricating agents include, but are not limited to stearates (e.g. magnesium, calcium, and sodium), stearic acid, Sterotex Registered, talc, waxes, and Stearowet Registered.
- the ethylcellulose KCI microcapsules coated with a plasticized polymer coating solution are blended with a diluent, preferably microcrystallme cellulose, optionally a disintegrant and/or a lubricant, and compressed into capsule shaped tablets.
- a disintegrant such as crosslinked PVP (Crospovidone) or sodium starch glycolate at a level of 0.2 to 2% w/w and/or a lubricant/surfactant such as sodium lauryl sulfate is optionally blended with the compression mix.
- a disintegrant such as crosslinked PVP (Crospovidone) or sodium starch glycolate at a level of 0.2 to 2% w/w
- a lubricant/surfactant such as sodium lauryl sulfate
- microcapsules fluid bed coated with the plasticized polymeric systems discussed in this patent application could be compressed into strong tablets with low friability without a lubricant (magnesium stearate) or a surfactant (sodium lauryl sulfate).
- a lubricant magnesium stearate
- a surfactant sodium lauryl sulfate
- the final tablets will contain a pharmaceutically acceptable amount of potassium chloride. Acceptable daily dosages may be found in The Physicians' Desk Reference, 45th ed. (1991), e.g., 20-200 mEq/day thereof, preferably from about 8 mEq to about 20 mEq.
- the pharmaceutically elegant 20 mEq Microcaps KCI tablets will exhibit sustained release properties (releasing not more than 40% in one hr and not less than 80% over 8 hrs when tested in USP Apparatus 2 (Paddles @ 50 rpm) in purified water, thereby providing treatments for potassium deficiency in humans with minimal adverse side effects.
- Example 1-3 Typical formulations are given in Example 1-3. Unless otherwise indicated all parts are by weight.
- Microcaps KCI granules (KCI crystals microencapsulated in ethylcellulose) with a 87.5 KCI content were coated with an aqueous solution of hydroxypropylmethyl cellulose (HPMC) and polyethylene glycol 400 (PEG 400) at a ratio of 77/23 to achieve a weight gain of 0.5% w/w.
- HPMC hydroxypropylmethyl cellulose
- PEG 400 polyethylene glycol 400
- the film coated granules were blended with microcrystalline cellulose (MCC), crosslinked PVP and sodium lauryl sulfate in an amounts of at 9.5%, 2.0% and 0.5% w/w, respectively and compressed into tablets weighing 1960 mg on a rotary tablet press.
- MMCC microcrystalline cellulose
- PVP polyethylene glycol 400
- Microcaps KCI granules (KCI crystals microencapsulated in ethylcellulose) with a 87.5 KCI content were coated to achieve a weight gain of 2.5% w/w with an aqueous solution of HPMC and PEG 400 at a ratio of 77/23.
- the film coated granules were blended with microcrystalline cellulose and crosslinked PVP at 10.0 and 1.0% w/w, respectively and compressed into tablets weighing 1989 mg on a rotary tablet press. These tablets containing 1500 mg active as Microcaps KCI release slowly over a period of 10 hrs when dissoluted in 0.1N HCL using USP Apparatus 2.
- Microcaps KCI granules (KCI crystals microencapsulated in ethylcellulose) with a 87.5 KCI content were coated with an aqueous solution of HPMC and PEG 400 at a ratio of 77/23 to achieve a weight gain of 1.0% w/w.
- the film coated granules were blended with microcrystalline cellulose, crosslinked PVP and magnesium stearate at 9.5%, 2.0 and 0.5% w/w, respectively and compressed into tablets weighing 1968 mg on a rotary tablet press.
- Microcaps KCI granules KCI crystals microencapsulated in ethylcellulose with a 87.5 KCI content were coated with an aqueous solution of polyvinylpyrrolidone (PVP K-30) containing 1 :1 PEG 400/PEG 4000 at 10% w/w to achieve a weight gain of 2.0% w/w.
- the film coated granules were blended with microcrystalline cellulose at 10.0% w/w and compressed into tablets weighing 1944 mg on a rotary tablet press. These tablets containing 1500 mg active as Microcaps KCI release slowly over a period of 10 hrs when dissoluted in 0.1N HC1 using USP Apparatus 2.
- Microcaps KCI granules KCI crystals microencapsulated in ethylcellulose with a 87.5 KCI content were coated to achieve a weight gain of 2.0% w/w with an aqueous solution of PVP and tri-ethyl citrate at a ratio of 97/03.
- the film coated granules were blended with microcrystalline cellulose and crosslinked PVP at 10.0 and 1.0% w/w, respectively and compressed into tablets weighing 1965 mg on a rotary tablet press. These tablets containing 1500 mg active as Microcaps KCI release slowly over a period of 10 hrs when dissoluted in 0.1N HC1 using USP Apparatus 2.
- Microcaps KCI granules KCI crystals microencapsulated in ethylcellulose with a 87.5 KCI content were coated with an IP A/acetone solution of PVP/Ethocel/DBS at a ratio of 48/48/04 to achieve a weight gain of about 2.0% w/w.
- the film coated granules were blended with microcrystalline cellulose at 10% w/w and compressed into tablets weighing 1944 mg on a rotary tablet press.
- These pharmaceutically elegant tablets containing 1500 mg active as Microcaps KCI release slowly over a period of 10 hrs when dissoluted in 0.1N HC1 using USP Apparatus 2.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002394588A CA2394588A1 (en) | 1999-12-16 | 2000-12-15 | Controlled release kcl tablet formulations |
EP00984388A EP1244429A1 (en) | 1999-12-16 | 2000-12-15 | Controlled release kci tablet formulations |
AU21013/01A AU2101301A (en) | 1999-12-16 | 2000-12-15 | Controlled release kci tablet formulations |
HK03102222.3A HK1051320A1 (en) | 1999-12-16 | 2003-03-27 | Controlled release kci tablet formulations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46508599A | 1999-12-16 | 1999-12-16 | |
US09/465,085 | 1999-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001043725A1 true WO2001043725A1 (en) | 2001-06-21 |
Family
ID=23846434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/033924 WO2001043725A1 (en) | 1999-12-16 | 2000-12-15 | Controlled release kci tablet formulations |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1244429A1 (en) |
AU (1) | AU2101301A (en) |
CA (1) | CA2394588A1 (en) |
HK (1) | HK1051320A1 (en) |
WO (1) | WO2001043725A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7632521B2 (en) * | 2003-07-15 | 2009-12-15 | Eurand, Inc. | Controlled release potassium chloride tablets |
EP2389174A2 (en) * | 2009-01-22 | 2011-11-30 | Abbot Healthcare Private Limited | Chronotherapeutic pharmaceutical composition |
EP2601936A1 (en) * | 2010-08-03 | 2013-06-12 | Eisai R&D Management Co., Ltd. | Compressed composition |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4716041A (en) * | 1984-02-10 | 1987-12-29 | A/S Alfred Benzon | Diffusion coated multiple-units dosage form |
US5397574A (en) * | 1993-10-04 | 1995-03-14 | Andrx Pharmaceuticals, Inc. | Controlled release potassium dosage form |
US5422122A (en) * | 1992-08-04 | 1995-06-06 | Eurand America, Incorporated | Controlled release potassium chloride tablet |
US5840329A (en) * | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
-
2000
- 2000-12-15 EP EP00984388A patent/EP1244429A1/en not_active Withdrawn
- 2000-12-15 CA CA002394588A patent/CA2394588A1/en not_active Abandoned
- 2000-12-15 AU AU21013/01A patent/AU2101301A/en not_active Abandoned
- 2000-12-15 WO PCT/US2000/033924 patent/WO2001043725A1/en not_active Application Discontinuation
-
2003
- 2003-03-27 HK HK03102222.3A patent/HK1051320A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4716041A (en) * | 1984-02-10 | 1987-12-29 | A/S Alfred Benzon | Diffusion coated multiple-units dosage form |
US5422122A (en) * | 1992-08-04 | 1995-06-06 | Eurand America, Incorporated | Controlled release potassium chloride tablet |
US5397574A (en) * | 1993-10-04 | 1995-03-14 | Andrx Pharmaceuticals, Inc. | Controlled release potassium dosage form |
US5840329A (en) * | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7632521B2 (en) * | 2003-07-15 | 2009-12-15 | Eurand, Inc. | Controlled release potassium chloride tablets |
EP2389174A2 (en) * | 2009-01-22 | 2011-11-30 | Abbot Healthcare Private Limited | Chronotherapeutic pharmaceutical composition |
EP2389174A4 (en) * | 2009-01-22 | 2014-05-07 | Abbot Healthcare Private Ltd | Chronotherapeutic pharmaceutical composition |
EP2601936A1 (en) * | 2010-08-03 | 2013-06-12 | Eisai R&D Management Co., Ltd. | Compressed composition |
EP2601936A4 (en) * | 2010-08-03 | 2014-03-19 | Eisai R&D Man Co Ltd | Compressed composition |
Also Published As
Publication number | Publication date |
---|---|
AU2101301A (en) | 2001-06-25 |
EP1244429A1 (en) | 2002-10-02 |
CA2394588A1 (en) | 2001-06-21 |
HK1051320A1 (en) | 2003-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4968508A (en) | Sustained release matrix | |
US4816264A (en) | Sustained release formulations | |
EP0660705B1 (en) | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine | |
US4610870A (en) | Controlled release formulation | |
US6476006B2 (en) | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates | |
EP0280571B1 (en) | Sustained release matrix formulations | |
US20040052844A1 (en) | Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins | |
US20030133982A1 (en) | Zero-order sustained release dosage forms and method of making same | |
US20040202718A1 (en) | Dosage form for treatment of diabetes mellitus | |
AU2001268719A1 (en) | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates | |
AU750617B2 (en) | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same | |
WO2001035958A1 (en) | Carvedilol methanesulfonate | |
JPH061716A (en) | Medical prescription having long-term releasability of active ingredient | |
KR20080037680A (en) | Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a ph modifier | |
US5422122A (en) | Controlled release potassium chloride tablet | |
US20120003307A1 (en) | Levetiracetam controlled release composition | |
CZ298851B6 (en) | Controlled-release tablet for oral administration of active substances | |
US20100285125A1 (en) | Delivery system for poorly soluble drugs | |
US20050013860A1 (en) | Controlled release potassium chloride tablets | |
EP1216032B1 (en) | Oral controlled release formulations | |
WO2003099214A2 (en) | Biguanide formulations | |
EP1244429A1 (en) | Controlled release kci tablet formulations | |
JP3282832B2 (en) | Sustained tablets | |
JPH06345649A (en) | Ipsapyrone pharmaceutical composition | |
US20040228918A1 (en) | Granule modulating hydrogel system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2394588 Country of ref document: CA Ref document number: PA/A/2002/005994 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 519696 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000984388 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 21013/01 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2000984388 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000984388 Country of ref document: EP |